Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 1142-1149

  Berlin, Jordan ^a   Stewart, James A ^a   Storer, Barry ^a   Tutsch, Kendra D ^a   Arzoomanian, Rhoda Z ^a   Alberti, Dona ^a   Feierabend, Chris ^a   Simon, Kris ^a   Wilding, George ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG METABOLITE; PENCLOMEDINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PERMISSIBLE DOSE; METHODOLOGY; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031887426     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.1142     Document Type: Article

References (21)

1. Benvenuto JA, Hittelman WN, Zwelling LA, et al: Biochemical pharmacology of penclomedine (NSC-338720). Biochem Pharmacol 50:1157-1164, 1995
2. Plowman J, Harrison SD, Dykes DJ, et al: Preclinical antitumor activity of an α-picoline derivative, penclomedine (NSC 338720), on human and murine tumors. Cancer Res 49:1909-1915, 1989
3. Harrison SD, Plowman J, Dykes DJ, et al: Preclinical antitumor activity of penclomedine in mice: Cross-resistance, schedule dependence, and oral activity against tumor xenografts in brain. Cancer Res 51:1979-1983, 1991
4. National Cancer Institute: Investigator's Brochure: Penclomedine. Bethesda, MD, National Cancer Institute, 1992; NSC 338720
5. Markman M: The ethical dilemma of phase I clinical trials. CA Cancer J Clin 36:367-369, 1986
6. Mick R, Ratain MJ: Model-guided determination of maximum-tolerated dose in phase I clinical trials: Evidence for increased precision. J Natl Cancer Inst 85:217-223, 1993
7. Christian MC, Korn EL: The limited precision of phase I trials. J Natl Cancer Inst 86:1662-1663, 1994
8. Estey E, Hoth D, Simon R, et al: Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep 70:1105-1115, 1986
9. Kodish E, Stocking C, Ratain MJ, et al: Ethical issues in phase I oncology research: A comparison of investigators and institutional review board chairpersons. J Clin Oncol 10:1806-1816, 1992
10. Geller NL: Design of phase I and II clinical trials in cancer: A statistician's view. Cancer Invest 2:483-491, 1984
11. Storer BE: Design and analysis of phase I clinical trials. Biometrics 45:925-937, 1989
12. Reid JM, Mathiesen DA, Benson LM, et al: Murine pharmacokinetics and metabolism of penclomedine [3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine, NSC 338720]. Cancer Res 52:2830-2834, 1992
13. Gibaldi M, Periier D: Pharmacokinetics (ed 2). New York, NY, Dekker, 1982
14. Hartman NR, O'Reilly S, Rowinsky EK, et al: Murine and human in vivo penclomedine metabolism. Clin Cancer Res 2:953-962, 1996
15. Storer B: Small-sample confidence sets for the MTD in a phase I clinical trial. Biometrics 49:1117-1125, 1993
16. O'Reilly S, Donehower RC, Chen TL, et al: Phase I and pharmacologic studies of penclomedine: A novel alkylating agent with prominent preclinical activity in breast cancer. J Clin Oncol 15:1974-1984, 1997
17. Collins JM, Zaharko DS, Dedrick RL, et al: Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 70:73-80, 1986
18. Gianni L, Vigano L, Surbone A, et al: Pharmacology and clinical toxicity of 4′-iodo-4′-deoxydoxorubicin: An example of successful application of pharmacokinetics to dose escalation in phase I trials. J Natl Cancer Inst 82:469-477, 1990
19. O'Quigley J, Pepe M, and Fisher L: Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 46:33-48, 1990
20. Simon R, Freidlin B, Rubinstein L, et al: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147, 1997
21. O'Reilly S, O'Hearn E, Rowinsky E, et al: Neuroanatomic studies of the cerebellar toxicity of penclomedine (Pen). Proc Amer Assoc Cancer Res 37:374-375, 1996